Dr. Irwin Goldstein, Sue Goldstein, Prof. Sheryl Kingsberg, and Dr. Rachel Rubin

Amsterdam, the Netherlands, 10 February 2023 – Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women diagnosed with Female Sexual Disorders (FSD), today announced the extension of its Scientific Advisory Board (SAB) with four independent leading medical scientists in the FSD field from the US: Dr. Irwin Goldstein, Sue Goldstein, Prof. Sheryl Kingsberg, and Dr. Rachel Rubin. The extension was established in the light of the start of preparations for Freya’s clinical development program for LybridoTM against Female Sexual Disorders in the United States. The first meeting with the new members took place on 4 February 2023 in Houston, US. The SAB is chaired by Freya’s Chief Medical Officer Dr. Jan van der Mooren.

In 2022 Freya announced the initiation of its SAB with experts from Europe: Prof. Annamaria Giraldi, Prof. Rossella Nappi, Prof. Cobi Reisman, Prof. Linda Vignozzi and Dr. Giovanni Corona, to design the European clinical program. The US members have been installed to further shape this highly important advisory body for the company. The SAB co-designs the clinical program for LybridoTM overseeing that the quality of research at Freya is maintained, as well as assessing its upcoming confirmatory clinical trials with LybridoTM.

Dr. Jan van der Mooren, Chief Medical Officer of Freya, stated:

“I am delighted that leading experts in the field of Female Sexual Disorders from the United States have now joined our Scientific Advisory Board. As most of them have been involved in the early phase studies of LybridoTM, I trust that with their help we will be able to successfully design a compelling clinical trial program that will meet the requirements of the FDA. We intend to submit our plans to the FDA soon.”

During the meeting on 4 February 2023, the SAB together with the Lybrido Clinical Project Team discussed the European clinical program to confirm the efficacy of LybridoTM in women suffering from Female Sexual Disorders, and they worked together on drafting the US clinical program that is expected to be presented to FDA this spring.


Scientific Advisory Board

The new members of the Scientific Advisory Board are:

Dr. Irwin Goldstein MD, IF

Dr. Goldstein is Director of Sexual Medicine at Alvarado Hospital, Clinical Professor of Surgery and Voluntary Clinical Professor of Obstetrics, Gynecology, & Reproductive Sciences at University of California San Diego, and practices medicine at San Diego Sexual Medicine. He is also Editor-in-Chief of Sexual Medicine Reviews and past Editor of The Journal of Sexual Medicine.  He is a past President of the International Society for the Study of Women’s Sexual Health (ISSWSH) and of the Sexual Medicine Society of North America (SMSNA). Dr. Goldstein has authored more than 350 publications as well as multiple book chapters and edited 6 textbooks in the field.

Sue Goldstein BA, CCRC, AASECT-CSE, IF

Mrs. Goldstein is an AASECT Certified Sexuality Educator and Clinical Research Manager at San Diego Sexual Medicine. She works with the staff of the Sexual Medicine program at Alvarado Hospital and works with regional support groups. Mrs. Goldstein is currently President of the International Society for the Study of Women’s Sexual Health (ISSWSH) and serves on the Scientific Review Committee of the International Society for Sexual Medicine (ISSM) as well as the Educational Projects, Fellowship and Female Sexual Function Committees of the Sexual Medicine Society of North America (SMSNA). Mrs. Goldstein is managing editor of Sexual Medicine Reviews, and she is associate editor of Textbook of Female Sexual Function and Dysfunction and Female Sexual Pain Disorders. She co-authored When Sex Isn’t Good and is author of multiple peer reviewed papers.

Prof. Sheryl Kingsberg, PhD

Professor Sheryl Kingsberg is Chief of the Division of Behavioral Medicine in the Department of Obstetrics & Gynecology at University Hospitals Cleveland Medical Center/MacDonald Women’s Hospital in Cleveland, and a Professor in the Departments of Reproductive Biology, Psychiatry and Urology at Case Western Reserve University School of Medicine. She is a past President of The North American Menopause Society and The International Society for the Study of Women’s Sexual Health (ISSWSH). Prof. Kingsberg is Associate Editor of Sexual Medicine Reviews, and has (co-) authored more than 160 scientific papers and books/book chapters.

Dr. Rachel Rubin MD, IF

Dr. Rachel Rubin is a Board Certified Urologist and Sexual Medicine Specialist, and Assistant Clinical Professor at the Department of Urology at Medstar Georgetown University. She is Associate Editor of Sexual Medicine Reviews, a reviewer of The Journal of Sexual Medicine, Section Editor for Female Sexual Medicine, and a reviewer for America Urological Association guidelines on Ejaculatory Dysfunction. Dr. Rubin is a member of the board of directors of the International Society for the Study of Women’s Sexual Health (ISSWSH), a member of the American Urological Association (AUA), serves on the social media committee of the Sexual Medicine Society of North America (SMSNA), and is a member of the International Society for Sexual Medicine (ISSM). She is an active social media educator on FSD, has (co-)authored multiple scientific papers and authored 4 book chapters.

Dr. Jan van der Mooren MD, PhD, MSc is Chairman of the SAB and Chief Medical Officer of Freya Pharma Solutions.


About Female Sexual Disorders

Among female sexual disorders, low sexual desire is consistently reported as the most common sexual complaint in women. As a result, many women are dissatisfied with their sex lives, which often affects their social and emotional wellbeing. Currently several definitions are being used. Hypoactive Sexual Desire Disorder (HSDD) is recommended by ISSWSH and is a sexual dysfunction in which women lack motivation or lose desire to have sex for at least six months, causing significant levels of personal distress. Female Sexual Interest/Arousal Disorder (FSIAD) is a sexual dysfunction that is defined in the 2013 version of the DSM-5 Diagnostic and Statistical Manual of Mental Disorders, a publication by the American Psychiatric Association, as a persistent lack or significant reduction of sexual interest and/or arousal. Persons can be medically diagnosed after having a well-defined number of symptoms causing clinically significant distress and which have persisted for a minimum of six months. The disorder is specified by severity level and subtyped into lifelong versus acquired, generalized versus situational.

About LybridoTM

A total of 20 phase 1 and phase 2a trials and large-scale phase 2b trials in 17 research sites in the US have been conducted to date. These trials have investigated the efficacy and safety of two novel on-demand pharmacological treatments that have been designed to treat two FSIAD subgroups: women with low sensitivity for sexual cues (LybridoTM) and women with dysfunctional over-activation of sexual inhibition (LybridosTM). LybridoTM increases central sexual motivation and physiological sexual responses, such as swelling of genitals and lubrication. The therapy can be taken ‘on-demand’ and helps to increase central sexual motivation from 3 to 6 hours after intake.

This treatment consists of a novel (dual-route, dual-release, fixed-dose) combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the phosphodiesterase type 5 (PDE 5) inhibitor, sildenafil. The inner-core component is coated with a delayed-immediate-release matrix to ensure that the peak plasma concentration of the PDE 5 inhibitor coincides with the window of increased sexual motivation induced by the sublingually administered testosterone. Thus, this combination enables an increase in genital arousal through an increase in responsivity to sexual stimuli.

About Freya Pharma Solutions

Freya Pharma Solutions is a late clinical stage company focused on developing effective pharmaceutical therapies for HSDD/FSIAD, building upon fifteen years of solid research. The company has two compounds in development, LybridoTM and LybridosTM, to address the range of potential causes of HSDD/FSIAD. Based in Amsterdam, The Netherlands, Freya aims to offer patients a convenient, personalized ‘on-demand’ solution for this recognized unmet medical need.


Please contact for further information:

Freya Pharma Solutions, Amsterdam

Marcel Wijma, Executive Director

E: marcel@freyapharmasolutions.com

For media

LifeSpring Life Sciences Communication, Amsterdam

Leon Melens

T: +31 6 538 16 427

E: lmelens@lifespring.nl